宫颈HPV持续感染患者应用膦甲酸钠联合重组人干扰素α2b治疗临床疗效观察

摘要

目的:探究膦甲酸钠联合重组人干扰素α-2b治疗人乳头瘤病毒(human papillomavirus,HPV)持续感染患者的临床疗效.方法:选取2014年4月至2016年4月我院接诊的120例宫颈HPV持续感染患者进行研究,随机分配治疗组65例、对照组55例患者,对照组采用重组人干扰素α-2b栓治疗,治疗组在对照组的基础上联合膦甲酸钠进行治疗,比较两组患者治疗的总有效率、HPV转阴率、宫颈炎指标评分以及出现不良反应情况.结果:治疗组患者的总有效率96.92％显著高于对照组的87.27％,差异有统计学意义(P＜0.05);治疗组患者HPV转阴率(92.31％)显著高于对照组(78.18％),差异有统计学意义(x2=4.8888,P=0.0270);治疗组患者HPV病毒载量判定的总有效率93.38显著高于对照组的83.64％,差异有统计学意义(x2=4.5688,P=0.0326);治疗组患者治疗后宫颈炎指标评分(1.35±0.57)分低于治疗前指标评分(3.24±0.33)分,差异有统计学意义(t=18.3373,P=0.0000);对照组患者治疗后宫颈炎指标评分(1.35±0.57)分低于治疗前指标评分(3.24±0.33)分,差异有统计学意义(t=19.4932,P=0.0000).治疗组宫颈炎指标评分(1.35±0.57)分明显低于对照组(2.01±0.35)分,差异有统计学意义(P＜0.05).两组患者均未出现不良反应.结论:膦甲酸钠联合重组人干扰素α2b治疗HPV持续感染患者疗效较好,且具有安全性.%Objectives:To investigate the clinical efficacy of sodium formate combined with recombinant human interferon α2b in the treatment of patients with persistent infection of human papillomavirus (HPV).Methods:120 patients with cervical HPV from April 2014 to April 2016 in our hospital were randomly assigned to treatment group (n =65) and control group (n =55).The control group were treated with recombinant human interferon α2b suppository treatment,and on its basis the treatment group were treated with foscarnet sodium.The total efficiency,the HPV negative rate,cervicitis index score and adverse reactions were compared between the two groups.Results:The total effective rate in the treatment group was 96.92％,significantly higher than the control group of 87.27％,with statistically significant difference (P ＜ 0.05).The HPV negative rate in the treatment group (92.31％) was significantly higher than that of the control group (78.18％),with statistically significant difference (x2 =4.8888,P =0.0270).The the total efficiency determined by the HPV virus load in the treatment group and control group was 93.38 and 83.64％ respectively,with statistically significant difference (x2 =4.5688,P =0.0326).The cervicitis index score in the treatment group after treatment was (1.35 + 0.57) points,lower than that before treatment of (3.24 ± 0.33) points,with statistically significant difference (t =18.3373,P =0.0000).The cervicitis index score of the control group after treatment and before treatment was (1.35 ± 0.57) and (3.24 ± 0.33) points respectively,with statistically significant difference (t =19.4932,P =0.0000).The score of cervical lesions (1.35 ± 0.57) in treatment group was significantly lower than that in control group (P =0.35),with statistically significant difference (P ＜ 0.05).No adverse reactions were found in the two groups.Conclusion:The efficacy and safety of HPV combined with recombinant human interferon α2b in the treatment of patients with persistent infection is high.